Partenaires

CNRS


Rechercher


Accueil > Actualités > Archives > 2012

27.03.2012 - Nouvel article de l’équipe "Reconnaissance cellulaire et glycobiologie" dans la revue "Vascular Pharmacology"

par Frapart - publié le , mis à jour le

Collet, G., Skrzypek, K., Grillon, C., Matejuka, A., El Hafni-Rahbia, B., Lamerant-Fayel, N. and Kieda, C.

Hypoxia control to normalize pathologic angiogenesis : potential role for endothelial precursor cells and miRNAs regulation

Vascular Pharmacology (sous presse) doi : 10.1016/j.vph.2012.03.001

Résumé :

Hypoxia, a critical parameter of the tumor microenvironment, controls endothelial/tumor cell interactions and is the key to tumor angiogenesis development. Under hypoxic stress, tumor cells produce factors that promote angiogenesis, vasculogenesis, tumor cell motility, metastasis and cancer stem cell selection.

Targeting tumor vessels is a therapeutic strategy that has lately been fast evolving from antiangiogenesis to vessel normalization as discussed in this review. We shall focus on the pivotal role of endothelial cells within the tumor microenvironment, the specific features and the part played by circulating endothelial precursors cells. Attention is stressed on their recruitment to the tumor site and their role in tumor angiogenesis where they are submitted to miRNAs-mediated de/regulation. Here the compensation of the tumor deregulated angiogenic miRNAs – angiomiRs - is emphasized as a potential therapeutic approach. The strategy is to over express anti-angiomiRs in the tumor angiogenesis site upon selective delivery by precursor endothelial cells as miRs carriers.